| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Hepatitis B Surface Antibody
Test CodeHBSAB
Alias/See Also
Epic: LAB472
Hepatitis B recombinant (HepB) titer
PHSAB, Personel Health HBSAB, LAB2382
Hepatitis B recombinant (HepB) titer
PHSAB, Personel Health HBSAB, LAB2382
Preferred Specimen
Specimen Type: Serum
Collection Container: Serum gel
Specimen Volume: 3 mL
Minimum Volume
0.5 mL
Other Acceptable Specimens
Collection Container: Red top
Instructions
Centrifuge and separate cells after clot formation and within 4 hours of collection.
Transport Container
Plastic vial
Specimen Stability
Room temperature: 3 days
Refrigerated: 7 days
Frozen: 1 month
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Unlabeled, mislabeled, wrong tube type, hemolyzed, QNS, exceeds specimen stability requirements.
Methodology
Chemiluminescent microparticle immunoassay (CMIA)
Setup Schedule
Daily
Report Available
Same day
Limitations
A non-reactive test does not exclude the possibility of exposure to hepatitis B virus.
Results obtained with this methodology cannot be used interchangeably with results from other methodologies.
The assay does not differentiate between vaccines and natural infections.
Reactive anti-HBs does not exclude co-infection with other hepatitis viruses.
Reference Range
See laboratory report
Clinical Significance
HBV is transmitted through direct contact with blood and body fluids. Modes of transmission include transfusion, needle puncture, contact with open wounds, sexual contact, and mother-infant contact during birth. In the US, the CDC recommends prenatal testing for all pregnant women to identify newborns from HBV carrier mothers that can benefit from early prophylactic treatment.
Average incubation is 6-8 weeks with a range of 1-6 months. Infection can be asymptomatic, but clinical signs include malaise, fever, gastroenteritis, and icterus. In adults ~95% recover from acute illness, but ~5% become chronic carriers. In neonates, up to 90% develop chronic HBV infection. Chronic HBV infection is associated with hepatocellular carcinoma.
Hepatitis B surface antibody (anti-HBs,) can be detected in infectious patients several weeks after exposure to the virus, and levels usually persist for life after the acute infection resolves. The presence of anti-HBS after acute HBV infection and loss of HBSAG can be a useful indicator of disease resolution.
Anti HBs can be induced by vaccination with hepatitis vaccine, which protects most recipients from acute hepatitis B infection. Vaccination is given serially, and recipients are tested for anti-HBs to determine immune status.
Average incubation is 6-8 weeks with a range of 1-6 months. Infection can be asymptomatic, but clinical signs include malaise, fever, gastroenteritis, and icterus. In adults ~95% recover from acute illness, but ~5% become chronic carriers. In neonates, up to 90% develop chronic HBV infection. Chronic HBV infection is associated with hepatocellular carcinoma.
Hepatitis B surface antibody (anti-HBs,) can be detected in infectious patients several weeks after exposure to the virus, and levels usually persist for life after the acute infection resolves. The presence of anti-HBS after acute HBV infection and loss of HBSAG can be a useful indicator of disease resolution.
Anti HBs can be induced by vaccination with hepatitis vaccine, which protects most recipients from acute hepatitis B infection. Vaccination is given serially, and recipients are tested for anti-HBs to determine immune status.
Performing Laboratory
Inova Laboratories
2832 Juniper Street
Fairfax, VA 22031
Last Updated: April 10, 2023
Last Review: N. Wolford, April 10, 2023